EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025

Home/EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025

EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025

Clinical Trials, Pharma & Healthcare

Publication ID:

GDA0417198

Publication Date:

April 01, 2017

Pages:

Publisher:

GlobalData

Region:

Global

$3,995.00

Need Custom Market Research Solution?

Want to commission a custom market research to suit your needs? We are here to help. Let us know.

Printer version

Send by email

PDF version

Tabs

Description

EpiCast Report: Cystic Fibrosis - Epidemiology Forecast to 2025

Summary

Cystic fibrosis (CF) is an inherited disorder that affects the cells that produce mucus, sweat, and digestive juices, causing severe damage to the lungs, digestive system, and other organs. In CF patients, a defective gene results in sticky and thick secretions that plug up tubes, ducts, and passageways. The signs and symptoms of CF vary depending on the severity of the disease. Most of the signs and symptoms of CF affect the respiratory system and digestive system.

GlobalData epidemiologists provided two different forecasts for the diagnosed incident and diagnosed prevalent cases of CF in the 7MM: a forecast based on registry data and a forecast adjusted for the underestimation of registry-based data. According to the forecast based on registry data, the diagnosed incident cases of CF in the 7MM will decrease from 1,925 cases in 2015 to 1,813 cases in 2025, at an Annual Growth Rate (AGR) of negative 0.58%. The US will have the highest number of diagnosed incident cases of CF among the 7MM throughout the forecast period, while Germany will have the lowest.

According to the forecast adjusted for underestimation of registry data, the diagnosed incident cases of CF in the 7MM will decrease from 2,217 cases in 2015 to 2,074 cases in 2025, at an AGR of negative 0.64%. The US will have the highest number of diagnosed incident cases of CF among the 7MM throughout the forecast period, while Germany will have the lowest.

GlobalData epidemiologists utilized peer-reviewed, country-specific studies to forecast diagnosed incident cases, diagnosed prevalent cases, and mortality due to CF in the 7MM from 2015-2025. Diagnosed prevalent cases were segmented by sex, age, specific mutation type, and MRSA infection to provide more detailed information about the patient population. GlobalData epidemiologists ensured that the forecast methodology was consistent across all the 7MM to allow for a meaningful comparison of CF across these markets.

Scope

- The Cystic Fibrosis (CF) EpiCast Report provides an overview of the risk factors and global trends of CF in the seven major markets (7MM) (US, France, Germany, Italy, Spain, UK, and Canada). It includes a 10-year epidemiology forecast of diagnosed incident cases of CF, diagnosed prevalent cases of CF, and CF mortality segmented by sex in these seven markets. Diagnosed prevalent cases of CF are further segmented by age (starting from zero years of age and up to 85 years and older), specific mutation type, and chronic Methicillin-resistant Staphylococcus aureus (MRSA) infection.
- The CF epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The CF EpiCast series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global CF market.
- Quantify patient populations in the global CF market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CF therapeutics in each of the markets covered.
- Identify the percentage of CF diagnosed prevalent cases by age, sex, specific mutation type, and MRSA infection.

Table of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4
2 Executive Summary 5
2.1 Related Reports 12
3 Epidemiology 13
3.1 Disease Background 13
3.2 Risk Factors and Comorbidities 14
3.3 Global Trends 15
3.3.1 Diagnosed Incidence and Diagnosed Prevalence 16
3.4 Forecast Methodology 18
3.4.1 Sources Used 18
3.4.2 Forecast Assumptions and Methods 25
3.4.3 Sources Not Used 34
3.5 Epidemiological Forecast for CF (2015-2025) 35
3.5.1 Diagnosed Incident Cases, Based on Registry Data 35
3.5.2 Diagnosed Prevalent Cases, Based on Registry Data 38
3.5.3 CF Mortality, Based on Registry Data 46
3.5.4 Diagnosed Incident Cases, Adjusted for Underestimation 49
3.5.5 Diagnosed Prevalent Cases, Adjusted for Underestimation 52
3.5.6 CF Mortality, Adjusted for Underestimation 59
3.6 Discussion 62
3.6.1 Epidemiological Forecast Insight 62
3.6.2 Limitations of the Analysis 63
3.6.3 Strengths of the Analysis 64
4 Appendix 65
4.1 Bibliography 65
4.2 Physicians and Specialists Included in this Study 67
4.3 High-Prescribing Physician Survey 69
4.4 About the Authors 69
4.4.1 Epidemiologist 69
4.4.2 Reviewers 70
4.4.3 Global Director of Therapy Analysis and Epidemiology 71
4.4.4 Global Head of Healthcare 71
4.5 About GlobalData 72
4.6 About EpiCast 72
4.7 Contact Us 73
4.8 Disclaimer 73

List of Tables
1.1 List of Tables
Table 1: Risk Factors and Comorbidities of CF 15
Table 2: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of CF (Based on Registry Data) 19
Table 3: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of CF (Based on Registry Data) 20
Table 4: 7MM, Sources Used for Segmentation of Diagnosed Prevalent Cases of CF by Specific Mutations (Based on Registry Data) 21
Table 5: 7MM, Sources Used to Forecast the Proportion of Diagnosed Prevalent Cases of CF by Chronic MRSA Infection (Based on Registry Data) 23
Table 6: 7MM, Sources Used to Forecast CF Deaths (Based on Registry Data) 24
Table 7: 7MM, Proportion of CF Cases Reported to Respective CF Registries (Primary Research) 24
Table 8: 7MM, Sources Not Used in the Epidemiological Analysis of CF 35
Table 9: 7MM, Diagnosed Incident Cases of CF, All Ages, Both Sexes, N, Selected Years 2015-2025 (Based on Registry Data) 36
Table 10: 7MM, Sex-Specific Diagnosed Incident Cases of CF, All Ages, N (Row %), 2015 (Based on Registry Data) 37
Table 11: 7MM, Diagnosed Prevalent Cases of CF, All Ages, Both Sexes, N, Selected Years 2015-2025 (Based on Registry Data) 39
Table 12: 7MM, Age-Specific Diagnosed Prevalent Cases of CF, Both Sexes, N (Row %), 2015 (Based on Registry Data) 40
Table 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of CF, All Ages, N (Row %), 2015 (Based on Registry Data) 42
Table 14: 7MM, Diagnosed Prevalent Cases of CF with Chronic MRSA Infection, All Ages, Both Sexes, N, Selected Years 2015-2025 (Based on Registry Data) 46
Table 15: 7MM, CF Deaths, All Ages, Both Sexes, N, Selected Years 2015-2025 (Based on Registry Data) 47
Table 16: 7MM, Sex-Specific CF Deaths, All Ages, N (Row %), 2015 (Based on Registry Data) 48
Table 17: 7MM, Diagnosed Incident Cases of CF, All Ages, Both Sexes, N, Selected Years 2015-2025 (Adjusted for Underestimation) 50
Table 18: 7MM, Sex-Specific Diagnosed Incident Cases of CF, All Ages, N (Row %), 2015 (Adjusted for Underestimation) 51
Table 19: 7MM, Diagnosed Prevalent Cases of CF, All Ages, Both Sexes, N, Selected Years 2015-2025 (Adjusted for Underestimation) 53
Table 20: 7MM, Age-Specific Diagnosed Prevalent Cases of CF, Both Sexes, N (Row %), 2015 (Adjusted for Underestimation) 54
Table 21: 7MM, Sex-Specific Diagnosed Prevalent Cases of CF, All Ages, N (Row %), 2015 (Adjusted for Underestimation) 56
Table 22: 7MM, Diagnosed Prevalent Cases of CF with Chronic MRSA Infection, All Ages, Both Sexes, N, Selected Years 2015-2025 (Adjusted for Underestimation) 59
Table 23: 7MM, CF Deaths, All Ages, Both Sexes, N, Selected Years 2015-2025 (Adjusted for Underestimation) 60
Table 24: 7MM, Sex-Specific CF Deaths, All Ages, N (Row %), 2015 (Adjusted for Underestimation) 61
Table 25: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2016 69

List of Figures
1.2 List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of CF, All Ages, Both Sexes, N, 2015 and 2025 (Forecast Based on Registry Data) 6
Figure 2: 7MM, Diagnosed Prevalent Cases of CF, All Ages, Both Sexes, N, 2015 and 2025 (Forecast Based on Registry Data) 7
Figure 3: 7MM, CF Deaths, All Ages, Both Sexes, N, 2015 and 2025 (Forecast Based on Registry Data) 8
Figure 4: 7MM, Diagnosed Incident Cases of CF, All Ages, Both Sexes, N, 2015 and 2025 (Forecast Adjusted for Underestimation) 9
Figure 5: 7MM, Diagnosed Prevalent Cases of CF, All Ages, Both Sexes, N, 2015 and 2025 (Forecast Adjusted for Underestimation) 10
Figure 6: 7MM, CF Deaths, All Ages, Both Sexes, N, 2015 and 2025 (Forecast Adjusted for Underestimation) 11
Figure 7: 7MM, Diagnosed Incident Cases of CF, All Ages, Both Sexes, N, 2015-2025 (Based on Registry Data) 36
Figure 8: 7MM, Sex-Specific Diagnosed Incident Cases of CF, All Ages, N, 2015 (Based on Registry Data) 38
Figure 9: 7MM, Diagnosed Prevalent Cases of CF, All Ages, Both Sexes, N, Selected Years 2015-2025 (Based on Registry Data) 39
Figure 10: 7MM, Age-Specific Diagnosed Prevalent Cases of CF, Both Sexes, N, 2015 (Based on Registry Data) 41
Figure 11: 7MM, Sex-Specific Diagnosed Prevalent Cases of CF, All Ages, N, 2015 (Based on Registry Data) 43
Figure 12: 7MM, Age-Standardized Diagnosed Prevalence of CF, All Ages, N, 2015 (Based on Registry Data) 44
Figure 13: 7MM, Diagnosed Prevalent Cases of CF with Specific Mutations, Both Sexes, All Ages, N, 2015 (Based on Registry Data) 45
Figure 14: 7MM, Diagnosed Prevalent Cases of CF with Chronic MRSA Infection, Both Sexes, All Ages, N, 2015 (Based on Registry Data) 46
Figure 15: 7MM, CF Deaths, All Ages, Both Sexes, N, Selected Years 2015-2025 (Based on Registry Data) 47
Figure 16: 7MM, Sex-Specific CF Deaths, All Ages, N, 2015 (Based on Registry Data) 49
Figure 17: 7MM, Diagnosed Incident Cases of CF, All Ages, Both Sexes, N, 2015-2025 (Adjusted for Underestimation) 50
Figure 18: 7MM, Sex-Specific Diagnosed Incident Cases of CF, All Ages, N, 2015 (Adjusted for Underestimation) 52
Figure 19: 7MM, Diagnosed Prevalent Cases of CF, All Ages, Both Sexes, N, Selected Years 2015-2025 (Adjusted for Underestimation) 53
Figure 20: 7MM, Age-Specific Diagnosed Prevalent Cases of CF, Both Sexes, N, 2015 (Adjusted for Underestimation) 55
Figure 21: 7MM, Sex-Specific Diagnosed Prevalent Cases of CF, All Ages, N, 2015 (Adjusted for Underestimation) 57
Figure 22: 7MM, Diagnosed Prevalent Cases of CF with Specific Mutations, Both Sexes, All Ages, N, 2015 (Adjusted for Underestimation) 58
Figure 23: 7MM, Diagnosed Prevalent Cases of CF with Chronic MRSA Infection, Both Sexes, All Ages, N, 2015 (Adjusted for Underestimation) 59
Figure 24: 7MM, CF Deaths, All Ages, Both Sexes, N, Selected Years 2015-2025 (Adjusted for Underestimation) 60
Figure 25: 7MM, Sex-Specific CF Deaths, All Ages, N, 2015 (Adjusted for Underestimation) 62

Report License Types

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Report Enquiry

Do you need more information about this report before making a purchase decision or wish to customize this report to suite your requirements?

If yes, then please use the form given below and we will get in touch with you immediately.

Kindly use your official email address and contact number to ensure speedy response.

Name *

Email *

Company

Contact Number *

Report Title *

Your Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Drag or click the correct shape to the grey "drop area".